Aclidinium bromide/formoterol

Drug Profile

Aclidinium bromide/formoterol

Alternative Names: Aclidinium bromide/formoterol fumarate; BrimicaGenuair; DuaklirGenuair; Formoterol fumarate/aclidinium bromide; KRP-AB1102F; LAS40464

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Laboratorios Almirall
  • Developer Almirall S.A.; AstraZeneca; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Nov 2016 AstraZeneca announces intention to submit NDA to US FDA and Japanese Ministry of Health, Labour and Welfare in 2018 and with the C FDA in 2019 (AstraZeneca pipeline, November 2016)
  • 18 Nov 2016 AstraZeneca initiates the phase III AMPLIFY trial for Chronic obstructive pulmonary disease in Ukraine, Spain, Poland, Israel, Czech Republic, Bulgaria and USA after July 2016 (NCT02796677)
  • 03 Sep 2016 Pooled efficacy data from phase III trials in Chronic obstructive pulmonary disease presented at the 26th Annual Congress of the European Respiratory Society (ERS - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top